Presumed acute enteric infections represent a major driver of emergency department presentations and hospital admissions across the globe. Over the past decade, infectious diarrhea hospitalizations have experienced notable diagnostic transformations due to technological innovation. Healthcare facilities have increasingly adopted multiplex gastrointestinal nucleic acid amplification testing to streamline microbial identification. In addition, hospitals have restructured testing algorithms for healthcare-associated infections. However, whether enhanced diagnostic modalities improve pathogen documentation rates or alter inpatient outcomes remains an important clinical question. Clinicians must evaluate recent national trends to guide diagnostic stewardship, optimize antimicrobial therapy, and improve patient care pathways.

Shifting Diagnostic Paradigms in Infectious Diarrhea Hospitalizations

Historically, diagnostic evaluations for acute gastroenteritis depended heavily on conventional stool culture, microscopy, and isolated toxin assays. Because these conventional methods require multiple days for definitive results, physicians frequently initiated empiric antibiotics without microbiological confirmation. In recent years, multiplex molecular syndromic panels have revolutionized diagnostic microbiology by detecting dozens of bacterial, viral, and parasitic pathogens simultaneously within hours. Furthermore, these platforms deliver rapid results that can theoretically guide timely clinical decision-making. Simultaneously, inpatient facilities have refined diagnostic protocols for Clostridioides difficile, transitioning from standalone nucleic acid amplification tests to multistep testing algorithms. These algorithms combine highly sensitive screening antigens with specific toxin enzyme immunoassays. Consequently, laboratories can more accurately distinguish active toxin-mediated disease from asymptomatic gastrointestinal colonization. Nevertheless, hospital systems display substantial heterogeneity in diagnostic adoption. While academic medical centers routinely utilize syndromic panels, resource-constrained facilities frequently continue utilizing targeted cultures due to cost constraints. Therefore, understanding the practical impact of these divergent diagnostic approaches remains essential for hospital clinicians.

National Trends in Pathogen Specification Rates

A large-scale nationwide cross-sectional investigation utilizing the National Inpatient Sample evaluated adult hospital admissions between 2016 and 2023. The study analyzed more than 1.17 million hospitalizations with a primary discharge diagnosis of presumed infectious enteritis. Surprisingly, despite the rapid clinical rollout of molecular testing, pathogen specification rates remained remarkably stable over the eight-year study duration. Overall, 60.5 percent of admissions documented a specified microbial pathogen, with annual rates fluctuating narrowly between 59.6 percent and 62.1 percent. Multivariable statistical modeling confirmed no significant temporal increase in pathogen documentation over time. Consequently, nearly forty percent of all admitted patients continued to receive nonspecific diagnostic codes upon discharge. Several factors explain this persistent diagnostic stability. Specifically, widespread variation in laboratory capabilities, variable insurance reimbursement, and institutional testing restrictions prevent uniform adoption of broad molecular panels. Moreover, clinicians frequently manage mild or resolving gastroenteritis with supportive care alone, bypassing detailed microbiological workups. Therefore, expanding technological availability has not automatically translated into higher rates of pathogen specification at the national level.

The Significant Inpatient Decline of Clostridioides Difficile

Although aggregate pathogen documentation remained flat, researchers observed profound compositional shifts among specific enteropathogens during the study period. Most notably, hospitalizations attributed to Clostridioides difficile exhibited a substantial and progressive decline across the nation. In 2016, C. difficile accounted for 53.7 percent of all primary infectious diarrhea hospitalizations. However, by 2023, this proportion dropped substantially to 41.2 percent, demonstrating a statistically significant downward trend. Several decisive public health and diagnostic factors drove this favorable reduction. First, hospitals nationwide implemented rigorous infection prevention measures, including strict isolation precautions and dedicated sporicidal cleaning protocols. Second, widespread antimicrobial stewardship initiatives curbed the inappropriate use of high-risk antibiotics, such as fluoroquinolones and broad-spectrum cephalosporins. Third, diagnostic stewardship programs actively discouraged indiscriminate molecular testing for C. difficile. By requiring multistep toxin enzyme assays, laboratories successfully avoided misclassifying colonized patients as active infections. As a result, coding for true clinical colitis decreased appropriately. Thus, these combined interventions have achieved tangible progress in controlling healthcare-associated diarrhea.

Clinical Implications of Multiplex Molecular Diagnostics

The increasing utilization of syndromic multiplex gastrointestinal panels introduces substantial clinical benefits alongside distinct diagnostic challenges. Because these assays rapidly identify common viral pathogens such as norovirus and rotavirus, physicians can confidently withhold unnecessary empiric antibiotics. Furthermore, rapid detection of invasive bacterial pathogens allows clinicians to administer targeted antimicrobial regimens promptly when clinically indicated. However, the remarkable analytical sensitivity of molecular panels also creates clinical ambiguity. For example, these panels frequently detect latent organisms, persistent non-viable nucleic acid fragments, or asymptomatic colonization. Consequently, clinicians face genuine dilemmas when distinguishing true acute infection from incidental carriage, especially in patients with inflammatory bowel disease or irritable bowel syndrome. In addition, syndromic panels regularly detect polymicrobial co-infections, complicating the selection of targeted therapies. Uncritical reliance on positive panel results can inadvertently lead to overtreatment, inappropriate isolation, and escalating inpatient costs. Therefore, leading professional societies strongly emphasize that clinicians must correlate molecular test results with clinical presentations before altering management.

Diagnostic Stewardship and Practical Clinical Strategies

Effective inpatient management of acute diarrhea requires disciplined diagnostic stewardship combined with evidence-based supportive care. Hospital clinicians should avoid ordering indiscriminate multiplex molecular testing for every patient presenting with loose stools. Instead, testing should focus on individuals with high-risk clinical features, including severe dehydration, persistent high fever, gross hematochezia, or systemic toxicity. Immunocompromised patients and elderly individuals also warrant early, thorough microbiological evaluations to prevent severe decompensation. Meanwhile, aggressive fluid resuscitation, electrolyte repletion, and hemodynamic monitoring must remain the foundational pillars of therapy. When physicians obtain stool studies, they should interpret positive results cautiously in light of the patient’s clinical course. Moreover, hospital teams must maintain robust environmental cleaning and contact precautions to halt enteric transmission within wards. Antimicrobial stewardship programs must also continue auditing inpatient antibiotic selections to protect intestinal microflora and prevent secondary C. difficile colitis. By balancing thoughtful diagnostic selection with targeted therapeutic restraint, inpatient physicians can optimize clinical outcomes while minimizing unnecessary healthcare expenditure.

Why have pathogen specification rates remained stable despite newer molecular panels?

Pathogen specification rates have remained stable because molecular panel adoption is not uniform across all healthcare facilities. Many community hospitals still rely on conventional stool cultures and targeted assays due to budget constraints. In addition, clinicians frequently manage uncomplicated gastroenteritis empirically with oral rehydration alone, deliberately omitting extensive laboratory testing. Consequently, national documentation rates reflect persistent clinical selectivity rather than technological limitations.

What factors drove the national decline in Clostridioides difficile hospitalizations?

The decline in Clostridioides difficile hospitalizations results from coordinated hospital infection control and diagnostic stewardship. Dedicated sporicidal cleaning protocols and prompt patient isolation have significantly curtailed nosocomial transmission. Furthermore, hospital antibiotic stewardship teams have successfully reduced the overprescription of high-risk broad-spectrum antibiotics. Finally, adopting multistep diagnostic algorithms has eliminated false-positive diagnoses by effectively separating active toxin-mediated disease from benign asymptomatic bacterial colonization.

When should hospital clinicians order multiplex gastrointestinal testing for patients?

Clinicians should reserve multiplex gastrointestinal panels for patients with severe illness, persistent fever, bloody diarrhea, or marked systemic toxicity. In addition, immunocompromised individuals and frail elderly patients benefit from rapid molecular identification to direct targeted antimicrobial therapy. Conversely, physicians should avoid routine testing in mild, self-limiting gastroenteritis, because molecular panels frequently detect non-pathogenic bystander organisms or prolonged viral shedding, leading to unnecessary treatments.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Arias DW et al. National trends in pathogen-specific diagnoses and outcomes among hospitalizations for infectious diarrhea. J Hosp Med. 2026 Sep 03. doi: 10.1002/jhm.70454. PMID: 42689444.
2. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017;65(12):e45-e80.
3. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the IDSA and SHEA. Clin Infect Dis. 2018;66(7):e1-e48.
4. Alhifany AA, Halloush S, Almangour TA, et al. Diagnostic stewardship of multiplex gastrointestinal panels: A systematic review. Am J Infect Control. 2023;51(8):923-930.